Granules India Ltd. INR 113
|
|
- Veronica Dixon
- 8 years ago
- Views:
Transcription
1 India Equity Institutional Research Pharma RESULT UPDATE Granules India Ltd. INR 113 Misses expectation BUY Result highlights Net sales for the quarter grew by a moderate 8% YoY to INR 3,449mn below our estimates. Auctus Pharma contributed around INR 300mn to sales with a small profit of INR 2mn at PBT level. EBIDTA grew by a healthy 24% YoY to INR 677mn & EBITDA margins stood at 19.6% expanding by 260bps mainly due to operational efficiency in base business and superior product mix. PAT grew by 15% YoY to INR 272mn on account of a higher tax rate at 33%. The Board of directors declared third interim dividend of 15p/share. Expansion of manufacturing facilities to enhance base business growth: During the quarter, around 33% of sales were contributed from FDs, 27% from PFIs & 40% from APIs. FDs and PFIs are high margin business compare to APIs. Company is also expanding Metformin API capacity at Bonthapally to 9000 tonnes from current 2000 tonnes. Management expects Phase 1 of expansion to complete by August We believe base business growth to improve once the company starts using the benefit of expanded facility. Management has guided sales contribution from FDs will reach 65% at peak level in 5 years time. Company posted sales of around INR 42mn from Abacavir during the quarter. Company is planning to launch additional 4-5 APIs during the year and has filed a multiple sclerosis API with market size of USD 4bn. Going forward we believe company will continue its momentum from the existing and newly commissioned facilities which will lead to top line growth, utilization as well as margin improvement. We expect revenue CAGR of around 15% over FY15-18E & operating margins to be around 19%. Commercialisation from Omnichem JV to drive growth: Company has entered into the high margin CRAMS business through JV (50:50) with Ajinomoto Omnichem. Management has highlighted that the plant has commissioned & guided revenues to be around INR mn at JV level. Peak sales are expected to be around INR 5,500mn through this JV & operating margins expected to be 20%. We believe this JV will contribute significantly to earnings post FY17. Ramp up in Auctus portfolio basket Auctus pharma contributed around INR 300mn to revenues during the quarter. Granules strategy is to produce API in house and then gradually shift into formulation of same molecule. For this, company will be filing 3-4 ANDAs (including Auctus & Owned) in next 12 months & 10 ANDAs by FY17. Granules is focusing on improving the product mix with more focus on regulated markets which will help operating margins to expand going ahead. We expect strong growth trajectory from turning around of Auctus and expect margins to improve significantly. Valuation: Granules India has achieved a whopping 28% CAGR in revenues & 36% CAGR in earnings over the past 10 years. We expect a healthy earnings momentum to kick-start on account of Granules moving up the value chain towards high margin business, improved capacity utilization & additional product offerings from Auctus Pharma. We expect revenue and earnings CAGR of around 17% and 28% respectively over FY15-18E. Currently the stock is trading at 15x of FY17E & 12x of FY18E EPS. We upgrade our rating to BUY from ACCUMULATE with the target price of INR 160 at 17xFY18E. Key Financials Particulars FY14 FY15 FY16E FY17E FY18E Revenues 10,959 12,929 14,651 17,605 20,747 EBITDA 1,583 2,086 2,725 3,389 4,087 APAT ,191 1,542 1,923 AEPS P/E (x) EV/EBITDA (x) RoE (%) Target Price (INR): 160 Potential upside : 42% Market Data Shares outs (mn) 213 EquityCap (INR mn) 213 Mkt Cap (INR mn) 25, Wk H/L (mn) 164/75 Volume Avg (3m K) 1,329 Face Value (INR) 1 Bloomberg Code Market Info: GRAN IN SENSEX 24,469 NIFTY 7,425 Price Performance Shareholding pattern (%) Particulars Dec15 Sep15 Jun15 Promoters FIIs DIIs Others Total Source: BSE Name of Analyst: Hemanshu Srivastava hemanshu.srivastava@krchoksey.com KRChoksey Research is also available on Bloomberg KRCS<GO>, Thomson Reuters, Factset and Capital IQ January 29, 2015
2 Q2FY16 Result Snapshot Profit & Loss account INR mn Q3FY16 Q2FY16 Q3FY15 QoQ (%) YoY (%) Net Sales 3,449 3,664 3,197 (6) 8 Other operating income Total Income 3,449 3,664 3,197 (6) 8 Expenditure 2,772 2,975 2,652 (7) 5 Materials Consumed 1,755 2,004 1,762 (12) (0) % of sales Manufacturing Expenses % of sales Employee Cost % of sales R&D Expenses % of sales Other Exp % of sales EBITDA (2) 24 EBITDA margin (%) Depreciation EBIT (4) 25 Other Income Interest expenses PBT (5) 29 Tax Effective tax rate (%) PAT (12) 15 APAT (12) 15 Adj. Net Margin (%) EPS (INR/share) Quarterly financial Performance Change in Estimates INR mn FY16E FY17E FY18 Old New %Chg Old New %Chg Old New %Chg Revenue 15,131 14,651 (3.2) 18,294 17,605 (3.8) 21,863 20,747 (5.1) EBITDA 2,799 2,725 (2.7) 3,458 3,389 (2.0) 4,132 4,087 (1.1) EBITDA Margin (%) PAT 1,291 1,191 (7.7) 1,652 1,542 (6.7) 2,048 1,923 (6.1) EPS (INR) (7.7) (6.7) (6.1) 2 KRChoksey - Institutional Research
3 Quarterly sales trend Quarterly EBITDA and EBITDA margins trend Geography wise quarterly revenue distribution (in %) Vertical wise quarterly revenue breakup (in %) Molecule wise revenue quarterly breakup (in %) Molecule wise revenue yearly breakup (in %) Annual vertical wise production trend 3 KRChoksey - Institutional Research
4 Geography wise yearly revenue distribution (in %) Vertical wise yearly revenue breakup (in %) Concall highlights: Granules entered into a partnership agreement with Par Pharmaceuticals to market generic version of Merck s Zegerid OTC (Omeprazole and Sodium Carbonate). As per the management, the current market size for the product is USD 40mn, with the expected approval date from the US FDA for the gzegerid to be in July 2016 following patent expiry on July 15, The management is hopeful of generating revenues in tune of USD 4-5mn from this product. During the quarter, Granules Jeedimetla and Vizag plant were inspected by US FDA. Jeedimetla received 3 observations in Form 483 relating to procedural and standard operating procedures such as complaint registration procedures, equipment cleaning etc. There were no data integrity issues highlighted by the FDA at Granules plant in Jeedimetla. Vizag plant successfully passed US FDA inspection without any Form 483. Management has guided that current growth is sustainable in the future on account of PFI capacity expansion and better product mix which will lead to better operational efficiency. Paracetamol, Metformin, Ibuprofen, Guafenesin, Methacarbonal & others contributed around 38%, 23%, 21%, 6%, 1% & 11% of sales respectively during the quarter. FDs contributed around 33%, PFIs 27%, and APIs 40% of consolidated sales during Q3FY16. Started sales of Ibuprofen Rx in the US markets in September 2015 with sales of INR 150mn from the product during the quarter. The market size for this product stands at around INR 4,000-5,00mn with Dr. Reddy s and Amneal being the only players in the market. Omnichem JV sales for the quarter stood at INR 120mn with margins at ~20% due to some production barrier. Granules has booked sales of ~INR 17mn for this quarter compared to INR 42mn in Q2FY16. The management expects enhanced visibility from its Omnichem JV going forward with sales expected to be in the range of INR 1,500-2,000mn in FY17. Regulated markets contributed 59% with US contributing 34% followed by Europe (19%) and Canada (6%). RoW markets contributed 41% of sales comprising of India (19%), Latam (10%), MENA (11%) and Australia (1%). Auctus posted INR 300mn of sales with a small profit of INR 2mn at PBT level during the quarter. This was aided by portfolio rationalization done by the management for two low margin products. Abacavir reported sales of around INR 42mn during Q3FY16. Overall Biocause JV (50-50) sales stood at INR 670mn for this quarter with INR 43mn in profit during the quarter. Company identified one API in multiple sclerosis space and has made the filing for the same in this quarter. Market size of this drug is estimated at around USD 4bn. The management expects real revenue generation to start from 2019/2020 onwards. Capex for Phase-I Metformin capacity expansion (3600 tonnes) is INR mn which will be completed by Aug-16. Capex for Phase-II expansion (3400 tonnes) will be INR mn will be in FY17. Overall capex for the 9MFY16 stood at INR 770mn with FY16 capex to be around INR 1,000mn. The company has filed for 3 DMFs during the quarter for Guafenesin, Methacarbonal and Metformin. EBITDA margins enhancement during the quarter was led by portfolio rationalization of 2 products from Auctus and oil price decline leading to lower raw material costs with sales being lower due to one of the partner facing formulation issues for its products whose main raw material supply is from Granules, thereby impacting sales. Long term loans stood at INR 3,480mn and working capital loans stood at INR 1,140mn for December KRChoksey - Institutional Research
5 Consolidated Financial Statements Income statement INR mn FY14 FY15 FY16E FY17E FY18E Revenues 10,959 12,929 14,651 17,605 20,747 Op. Expenses 9,376 10,843 11,926 14,216 16,660 EBITDA 1,583 2,086 2,725 3,389 4,087 Other Income Depreciation EBIT 1,328 1,603 2,179 2,713 3,332 Interest PBT 1,124 1,280 1,778 2,301 2,870 Tax PAT ,191 1,542 1,923 Minority Sh. of Associates Ex. ordinary Adj Pat ,191 1,542 1,923 Balance Sheet INR mn FY14 FY15 FY16E FY17E FY18E Equity Share Capital Reserves & Surplus 3,357 4,107 5,179 6,601 8,405 Total Shareholders Fund 3,560 4,312 5,383 6,806 8,609 Minority Interest Non- current liabilities 3,435 3,626 4,165 3,995 3,996 Long term Borrowings 3,092 3,082 3,620 3,450 3,451 Deferred tax liabilities Other LT liabilities & provisions Current Liabilities 2,925 4,034 3,795 4,248 4,852 Short-term borrowings 1,009 1,250 1,120 1,100 1,101 Trade payables 1,355 1,887 1,876 2,239 2,616 Other cur liabilities & Provisions ,134 Total Liabilities 9,920 11,971 13,343 15,048 17,456 Assets Non- current Assets 6,116 7,024 8,003 9,447 11,200 Fixed assets 6,070 6,786 7,765 9,209 10,962 Non-current investments Long-term loans & adv Other non-current assets Current assets 3,769 4,948 5,340 5,602 6,256 Current investments Trade receivables 1,109 1,326 1,525 1,688 1,989 Inventories 1,742 2,245 2,328 2,653 3,126 Cash & bank balances Short-term loans & adv Other current assets Miscellaneous Total Assets 9,920 11,971 13,343 15,048 17,456 5 KRChoksey - Institutional Research
6 Cash Flow Statement INR mn FY14 FY15 FY16E FY17E FY18E PBT 1,124 1,280 1,778 2,301 2,870 Depreciation Interest Exp Others CF before W.cap 1,628 2,133 2,775 3,447 4,153 Inc/dec in W.cap (310) (363) (247) (39) (184) Op CF after W.cap 1,317 1,771 2,528 3,408 3,969 Less Taxes (238) (317) (587) (759) (947) Others Net CF From Operations 1,079 1,453 1,942 2,648 3,022 Inc/(dec) in F.A + CWIP (2,649) (1,475) (1,575) (2,177) (2,575) (Pur)/sale of Investments Others CF from Invst Activities (2,546) (1,456) (1,575) (2,177) (2,575) Loan Raised/(repaid) 1, (602) (460) Equity Raised Dividend (47) (83) (119) (119) (119) CF from Fin Activities 1, (112) (721) (579) Net inc /(Dec) in cash (251) (133) Op. bal of cash Cl. balance of cash Ratio Analysis Particulars FY14 FY15 FY16E FY17E FY18E Per share INR EPS CEPS BVPS DPS Payout (%) Valuation (x) P/E P/BV EV/EBITDA Dividend Yield (%) Return ratio (%) EBIDTA Margin PAT Margin ROAE ROACE Leverage Ratios (x) Long Term D/E Net Debt/Equity Debt/EBITDA Interest Coverage Current ratio Growth Ratios (%) Income growth EBITDA growth PAT growth Turnover Ratios F.A Turnover x Inventory Days Debtors Days Payable days KRChoksey - Institutional Research
7 Granules India Ltd. Date CMP (Rs) TP (Rs) Recommendation 28-Jan BUY 02-Nov ACCUMULATE 14-Oct HOLD 24-Jul ACCUMULATE 29-April BUY 9-April BUY 29-Jan BUY 14-Jul BUY Rating Legend Our Rating Upside Buy More than 15% Accumulate 5% - 15% Hold 0 5% Reduce -5% 0 Sell Less than -5% ANALYST CERTIFICATION: I, Hemanshu Srivastava (BE & MBA) research analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Terms & Conditions and other disclosures: KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and MCX Stock Exchange Limited. KRCSSPL is in the process of making an application with SEBI for registering as a Research Entity in terms of SEBI (Research Analyst) Regulations, We submit that no material disciplinary action has been taken on KRCSSPL and its associates by any Regulatory Authority impacting Equity Research Analysis activities. KRCSSPL generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. The information and opinions in this report have been prepared by KRCSSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavor to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. KRCSSPL or its associates might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services. KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts have any material conflict of interest at the time of publication of this report. It is confirmed that, Hemanshu Srivastava (BE & MBA) research analyst/associate of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions. KRCSSPL or its associates collectively or its research analyst do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst. Since associates of KRCSSPL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. It is confirmed that, Hemanshu Srivastava (BE & MBA) research analyst/associate do not serve as an officer, director or employee of the companies mentioned in the report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Please send your feedback to research.insti@krchoksey.com Visit us at Kisan Ratilal Choksey Shares and Securities Pvt. Ltd Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai Phone: ; Fax: Corporate Office: ABHISHEK, 5th Floor, Link Road, Andheri (W), Mumbai Phone: ; Fax: KRChoksey - Institutional Research
Gujarat State Petronet Ltd. INR 135
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Oil & Gas RESULT UPDATE Gujarat State Petronet Ltd. INR 135 Growth in volumes to propel earnings Accumulate Gujarat
More informationMinda Industries Ltd. INR 886
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Automobiles RESULT UPDATE Minda Industries Ltd. INR 886 Profit boosted by margins ACCUMULATE In Q3FY16, Minda Industries
More informationGAIL (India) Ltd. INR 346
Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 India Equity Institutional Research Oil & Gas RESULT UPDATE GAIL (India) Ltd. INR 346 Good performance; Near term outlook looks stable BUY GAIL reported
More informationCipla Ltd. Rs. 741. India Equity Institutional Research Pharma. One off revenues from Nexium supply drives earnings HOLD. Target Price (Rs): 765
India Equity Institutional Research Pharma RESULT UPDATE Cipla Ltd. Rs. 741 One off revenues from Nexium supply drives earnings HOLD Result highlights Cipla s Q1FY16 result beats our estimates due to higher
More informationKotak Mahindra Bank Rs 685
India Equity Institutional Research BANKS RESULT UPDATE Kotak Mahindra Bank Rs 685 Smooth merger; benefits to accrue HOLD KMB s consolidated PAT for Q4FY15 stood at INR 9.5 that primarily on the back of
More informationCipla Ltd. INR 542. India Equity Institutional Research Pharma. Muted quarter; outlook remains robust. Target Price (INR): 646. Potential Upside : 19%
India Equity Institutional Research Pharma RESULT UPDATE Cipla Ltd. INR 542 Muted quarter; outlook remains robust BUY Result highlights Cipla s Q3FY16 Net Sales, EBITDA and PAT were below our estimates.
More informationGraphite Electrodes. Imposition of antidumping duty augurs well. Sector Update. ICICI Securities Ltd Retail Equity Research.
Sector Update Rating matrix Target price Company Old New CMP Potential Upside HEG 225 275 238 19% Graphite India 85 15 91 18% Target period 12-15 months Price performance (%) Return % 1M 3M 6M 12M HEG
More informationPI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI
$Com panyname$ Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) HOLD PI Industries Ltd. Custom synthesis
More informationFlexituff International Ltd. (FIL)
s $CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 (Wholly owned subsidiary of Bank of Baroda) Q2FY16 Result Review BUY Flexituff International Ltd. (FIL)
More informationICICI BANK INR 233. Dismal asset quality performance. Target Price (INR): 314. India Equity Institutional Research BFSI.
India Equity Institutional Research BFSI RESULT UPDATE ICICI BANK INR 233 Dismal asset quality performance BUY Q3FY15 earnings for ICICI Bank came as a huge disappointment with bank reporting highest NPAs
More informationQuant Picks United Breweries
October 6, 2015 Quant Picks United Breweries Research Analyst Amit Gupta amit.gup@icicisecurities.com Raj Deepak Singh rajdeepak.singh@icicisecurities.com Azeem Ahmad azeem.ahmad@icicisecurities.com i
More informationStrong operational performance
ABB India Equity Research Engineering & Capital Goods February 8, 2016 Result Update Emkay Your success is our success Strong operational performance CMP Target Price Rs1,134 Rs1,407 ( ) Rating Upside
More informationAxis Bank INR 521. Target Price (INR): 600. Staunch operating metrics; but blemish asset quality. Potential Upside: 15.16%
India Equity Institutional Research BANKS RESULT UPDATE Axis Bank INR 521 Staunch operating metrics; but blemish asset quality ACCUMULATE With strong operating performance, Axis Bank reported net profit
More informationHCC BUY. Infrastructure January 29, 2016
Jan-15 Mar-15 Apr-15 May-15 Jul-15 Aug-15 Sep-15 Nov-15 Dec-15 Jan-16 India Research Infrastructure January 29, 2016 QUARTERLY REVIEW Bloomberg: IN Reuters: HCNS.BO BUY Better margins drive earnings s
More informationNavin Fluorine International
RESULTS REVIEW 2QFY16 29 OCT 2015 Navin Fluorine International INDUSTRY CHEMICALS CMP (as on 29 Oct 2015) Rs 1,579 Target Price Rs 1,800 Nifty 8,112 Sensex 26,838 KEY STOCK DATA Bloomberg NFIL IN No. of
More informationKhambatta Securities Ltd.
Attractive Valuation Strong Buy Sector : Bank Private Target Price : Rs 284 Current Market Price : Rs 230 Market Cap : Rs 1,337 bn 52-week High/Low : Rs 393/216 Daily Avg. Volume : 13.88 mn Shares in issue
More informationMaruti Suzuki. Source: Company Data; PL Research
Q3 results subdued, Outlook remains good; BUY January 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs4,103 Target Price Rs4,844 Implied Upside 18.1% Sensex 24,470 Nifty
More informationSUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH
Q2FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH SUPREME INDUSTRIES LTD Plastic Products BSE CODE:509930 NSE CODE: SUPREMEIND Bloomberg CODE: SIL IN SENSEX: 24,470 HOLD CMP Rs725
More informationResults impacted by subdued demand
India Equity Research Agri Input & Chemicals January 25, 2016 Result Update Coromandel International Results impacted by subdued demand Emkay Your success is our success CMP Target Price Rs165 Rs225 (
More informationMangalam Cement Weak volumes marred performance
CMP* (Rs) 206 Market Cap. (Rs bn) 5.5 Free Float (%) 72 Shares O/S (mn) 26.7 Mangalam Cement Weak volumes marred performance Mangalam Cement (MCL) delivered a weak performance in 2Q but was marginally
More informationGlaxoSmithKline Consumer Healthcare
Strong pricing power, Attractive valuations "BUY" February 09, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs5,837
More informationShare gains with healthy margin uptick; Retain Buy
Colgate-Palmolive India Equity Research Consumers January 23, 2015 Result Update Emkay Your success is our success Share gains with healthy margin uptick; Retain Buy CMP Target Price Rs1,913 Rs1,940 (
More informationMphasis. FY17 could be a year of revenue growth. Source: Company Data; PL Research
FY17 could be a year of revenue growth February 08, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating Accumulate Price Rs440 Target Price Rs510 Implied Upside 15.9% Sensex 24,617 Nifty
More informationSimplex Infrastructures
2QFY216 Result Update Infrastructure November 17, 215 Simplex Infrastructures Performance Highlights Quarterly highlights - Standalone Y/E March (` cr) 2QFY16 1QFY16 2QFY15 % chg (yoy) % chg (qoq) Net
More informationBritannia Industries
Rally in Input costs near term drag, Maintain BUY June 20, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs2,641
More informationThe Ramco Cements. Source: Company Data; PL Research
Robust performance; remains the best play on Southern region February 09, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price
More informationBUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights
05 FEB 2016 Quarterly Update BUY Target Price: Rs 344 Muted Q3; Brands & Retail story to unfold Arvind s Q3 consolidated revenue at Rs 21.6 bn (Rs 20.7 bn in Q3FY15) was marginally below our estimate of
More informationSalzer Electronics. 2QFY16 Result Review BUY. Steady performance continued; maintain BUY. Sector: Electric Equipment
$CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Salzer Electronics Ltd. Steady
More informationTechno Electric & Engineering Limited
Engineering & Capital Goods Event Update Techno Electric & Engineering Limited Buy Wind business spin off will lead to value unlocking. Institutional Research CMP (`) 404 Target (`) 504 Nifty: 8,224 Sensex:
More informationAccumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH
Q3FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH Exide Industries Ltd(EIL) Automobile Ancillaries BSE CODE: 500086 NSE CODE: EXIDEIND Bloomberg CODE: EXID IN SENSEX: 23,759 Accumulate
More informationHigher other income drive the quarter
Gujarat State Petronet India Equity Research Oil & Gas February 4, 2016 Result Update Emkay Your success is our success Higher other income drive the quarter CMP Target Price Rs136 Rs163 ( ) Rating Upside
More informationHOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights
The case of missing sales growth Zydus Q3 net sales at Rs1.1 bn was up 3% on a like-to-like basis (Q3 15 had Rs 223 mn additional excise duty credit from prior periods), below our estimate of 6%. The company
More informationEmkay. Revenues traction improves; Retain BUY HSIL. Healthy revenue performance; miss on margins
HSIL India Equity Research Others February 3, 2016 Result Update Emkay Your success is our success Revenues traction improves; Retain BUY CMP Target Price Rs271 Rs370 ( ) Rating Upside BUY ( ) 36.6 % Healthy
More informationPolaris BUY. Virtusa acquires majority in Polaris. Institutional Equity Research. November 05, 2015. Target Price Rs220. IT India.
CMP* (Rs) 204 Market Cap. (Rs bn) 20 Free Float (%) 71 Shares O/S (mn) 100 Polaris Virtusa acquires majority in Polaris Virtusa Corp has purchased promoter and Citi s stake in Polaris of 53% for Rs220
More informationTree House Education & Accessories
2QFY2016 Result Update Educational Services November 10, 2015 Tree House Education & Accessories Performance Highlights Y/E March (` cr) 2QFY16 2QFY15 % chg (qoq) 1QFY16 % chg (yoy) Net sales 57 50 15.1
More informationBUY RSWM LTD SYNOPSIS. CMP 292.20 Target Price 336.00. SEPTEMBER 1 st 2015. Result Update(PARENT BASIS): Q1 FY16
BUY CMP 292.20 Target Price 336.00 RSWM LTD Result Update(PARENT BASIS): Q1 FY16 SEPTEMBER 1 st 2015 ISIN: INE611A01016 Index Details Stock Data Sector Textiles BSE Code 500350 Face Value 10.00 52wk. High
More informationJLR Nov-15 wholesale up 24% YoY to 51,021 units
BSE Sensex S&P CNX 25,036 7,613 9 December 2015 Update Sector: Automobiles Tata Motors CMP: INR394 TP: INR471 (+20%) Buy Stock Info Bloomberg TTMT IN Equity Shares (m) 3,395.9 M.Cap. (INR b)/(usd b) 1,338/20
More informationHOLD HEXAWARE TECHNOLOGIES. Q4 lackluster; CY16 holds promise. Target Price: Rs 252. Q4earnings concall highlights
05 FEB 2016 Quarterly Update HOLD Target Price: Rs 252 Q4 lackluster; CY16 holds promise Hexaware s Q4CY15 performance was lower than our estimates. Revenue growth and margin were largely impacted due
More informationBharat Electronics. Strong margins, improved inflows! Source: Company Data; PL Research
Strong margins, improved inflows! January 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,228 Target Price Rs1,353
More informationAurobindo Pharma. Source: Company Data; PL Research
Earnings in line; Strong guidance for FY17E maintained February 10, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs691 Target Price Rs943 Implied Upside 36.5% Sensex 23,759 Nifty
More informationResearch Analysts. September 30, 2015
Stocks on the move Scrip I-Direct Code Action Target Stoploss Hitachi Home and Life Solutions AMTAPP Buy in the range of 1380.00-1400.00 1640.00 1280.00 Time Frame: 3 Months Research Analysts Dharmesh
More informationResearch Analysts. Granules GRANUL Buy in the range of 142.00-146.00 168.00 133.00 EID Parry EIDPAR Buy in the range of 128.00-134.00 170.00 121.
Stocks on the move Scrip IDi I-Direct Code Action Target Stoploss Granules GRANUL Buy in the range of 142.00-146.00 168.00 133.00 EID Parry EIDPAR Buy in the range of 128.00-134.00 170.00 121.00 Time Frame:
More informationButterfly Gandhimathi (GANAP) 188
Result Update Rating matrix Rating : Buy Target : 240 Target Period : 12 months Potential Upside : 27% What s changed? Target EPS FY16E EPS FY17E Rating Quarterly performance Unchanged Unchanged Unchanged
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 SPS Finquest Ltd CMP: 84.60 January 13, 2015 Stock Details BSE code 538402 BSE ID SPS Face value ( ) 10 No of shares
More informationHOLD. Q4 earnings beat but order backlog flat ABB. Target Price: Rs 1,213. Key drivers
05 FEB 2016 Quarterly Update HOLD Target Price: Rs 1,213 Q4 earnings beat but order backlog flat s Q4CY15revenue at Rs24bnwasin line withour expectation of Rs24bn. EBITDA margin improved 290 bps YoYand
More informationJubilant Life Sciences
Radiopharma, Niacin continues to drive sales, margins October 30, 2015 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs401 Target Price Rs578 Implied Upside 44.1% Sensex 26,838 Nifty
More informationSmruthi Organics Limited BSE Scrip Code: 590046
Smruthi Organics Limited BSE Scrip Code: 590046 Pharmaceuticals September 21, 2012 Equity Statistics Current Market Price Rs. 218.1 52 Week High / Low Rs. 273.9 / 155 Market Capitalisation Rs. crores 83.2
More informationBUY. KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16. CMP 226.50 Target Price 260.00. JANUARY 9 th 2015 SYNOPSIS ISIN: INE164B01022
BUY CMP 226.50 Target Price 260.00 KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16 JANUARY 9 th 2015 ISIN: INE164B01022 Index Details Stock Data Sector IT Software Products BSE Code 519602
More informationVa Tech Wabag. Source: Company Data; PL Research
Weak execution, guidance hints a strong Q4FY16 February 08, 2016 Nishna Biyani nishnabiyani@plindia.com +91 22 66322239 Keyur Pandya keyurpandya@plindia.com +91 22 +91 22 66322247 Rating BUY Price Rs577
More informationRamKrishna Forgings Ltd.
January 3, 2014 RamKrishna Forgings Ltd. Poised for Growth CMP INR 81 Target INR 117.2 Coverage Follow Up BUY Key Share Data Face Value (INR) 10 Equity Capital (in INR Million) 211.0 Market Cap (in INR
More informationLarsen & Toubro. Source: Company Data; PL Research
Order inflow surprise, challenges on profitability continues! January 29, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating BUY Price Rs1,102
More informationIndia Equity Research Telecommunications September 2, 2015 Management Meet Update
Bharti Infratel India Equity Research Telecommunications September 2, 2015 Management Meet Update Emkay Your success is our success Data demand to accelerate growth CMP Rs396 Target Price Rs505 ( ) Rating
More informationJust Dial Ltd Bloomberg Code: JUST IN
Communications - Internet Media Oct 14, 215 Bloomberg Code: JUST IN India Research - Stock Broking India s local search engine, warming up with add-on services Just Dial is now into a platform where people
More informationResearch Analysts. June 30, 2016. Lupin LUPIN Buy in the range of 1520.00-1550.00 1770.00 1388.00
Stocks on the move Scrip IDi I-Direct tcode Action Target Stoploss Lupin LUPIN Buy in the range of 1520.00-1550.00 1770.00 1388.00 Time Frame: 3 Months Research Analysts Dharmesh Shah dharmesh.shah@icicisecurities.com
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 170.30 Target Price 196.00 GEOMETRIC LTD Result Update (CONSOLIDATED): Q2 FY16 DECEMBER 17 th 2015 ISIN: INE797A01021 12 th h, 2013 Index Details Stock Data Sector IT Consulting & Software BSE
More informationOutlook and valuation
February 9, 2016 Neutral Bajaj Auto Industry: Auto and Auto Components Industry View: Positive l Result Update Downgrade on export worries Q3 FY16 results came above our expectations despite exports worries
More informationJSW Energy Ltd. Interest expenses dragged the bottom-line BUY. Jan. 25, 2016
JSW Energy Ltd. Interest expenses dragged the bottom-line JSW Energy Ltd. (JSWEL) reported a mixed set of numbers for Q3 FY16 quarter. The company reported a consolidated total operating income of Rs.
More informationCMP: 1152.10 JUNE 2016 SWARAJ ENGINES LTD
Index Details SWARAJ ENGINES LTD Result Update (PARENT BASIS): Q4 FY16 Stock Data Sector Auto Parts & Equipment BSE Code 500407 Face Value 10.00 52wk. High / Low (Rs.) 1207.90/762.00 Volume (2wk. Avg.)
More informationDr. Reddy's Laboratories
Result in line; Tepid guidance for Q4FY16 on weak EM, currency February 10, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs2,960 Target Price Rs3,083 Implied Upside 4.2%
More informationUltraTech Cement Ltd.
Oct-11 Nov-11 Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 October 31, 212 COMPANY RESULTS REPORT REVIEW UltraTech Cement Ltd. Rich valuation overlooks strong performance
More informationRAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS. Earnings Presentation Q2 FY16
RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS Earnings Presentation Q2 FY16 Company Overview COMPANY OVERVIEW Rajesh Exports Ltd. (REL) was incorporated in 1989. Currently REL is a leader
More informationPidilite Industries. Source: Company Data; PL Research
Bountiful margin expansion in a tepid demand scenario February 03, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate
More informationBUY. ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16. CMP 1677.00 Target Price 1880.00. SEPTEMBER 2 nd, 2015 SYNOPSIS ISIN: INE738I01010
BUY CMP 1677.00 Target Price 1880.00 ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16 SEPTEMBER 2 nd, 2015 ISIN: INE738I01010 Index Details Stock Data Sector IT & ITes BSE Code 532927 Face
More informationSundaram Finance. Target price (INR) 452 Momentum in loans sustains, upgrade to Hold
HOLD Target price (INR) 452 Momentum in loans sustains, upgrade to Hold India Equity Research Financials January 30, 2013 Rating The higher than expected growth in the NII was driven by an improvement
More informationGladiator Stocks: Phillips Carbon Black (PHICAR) Time Frame: Six months
Gladiator Stocks: Phillips Carbon Black (PHICAR) Time Frame: Six months CMP: 160.00 00 Buying Range: 155.00-160.00 160 Target: 196.00 Stop loss: 137.00 Upside: 25% Stock Data 52 Week High / Low 162.95/80
More informationBUY. Lower realization impacts earnings CAIRN INDIA. Target Price: Rs 155. Analyst call highlights
25 JAN 2016 Quarterly Update BUY Target Price: Rs 155 Lower realization impacts earnings Despite flat QoQ oil and gas production, Cairn s Q3FY16 PAT slumped to Rs 87mn (vs. Rs 6,727 bn in Q2FY16) due to
More informationHOLD ASTRAL POLYTECHNIK. Q3 muted; recovery ahead. Target Price: Rs 377. Key highlights. Key drivers
11 FEB 2016 Quarterly Update HOLD Target Price: Rs 377 Q3 muted; recovery ahead Astral sq3fy16 results were impacted due to: (1) adverse raw-material prices in pipe division (~Rs 80 mn), (2) closure of
More informationCoal India Ltd. Subdued e-auction realization impacted profitability BUY. Nov. 17, 2015
17-Nov-14 17-Dec-14 17-Jan-15 17-Feb-15 17-Mar-15 17-Apr-15 17-May-15 17-Jun-15 17-Jul-15 17-Aug-15 17-Sep-15 17-Oct-15 Coal India Ltd. Subdued e-auction realization impacted profitability Coal India Ltd.
More informationBharti Infratel (BHAINF) 370
Result Update Rating matrix Rating : Buy Target : 500 Target Period : 12 months Potential Upside : 35% What s changed? Target Changed from 530 to 500 EPS FY16E Changed from 12.1 to 12 EPS FY17E Changed
More informationBUY GUJARAT STATE PETRONET. Operationally in line; other income surprises. Target Price: Rs 160. Valuations comfortable. Visible triggers ahead
05 FEB 2016 Quarterly Update BUY Target Price: Rs 160 Operationally in line; other income surprises GSPL s Q3FY16PAT at Rs 1.2bn was higher than our estimate (Rs 1.1bn) due to higher other income at Rs
More informationHCL Technologies BUY. Performance Highlights CMP. `857 Target Price `1,132. 1QFY2016 Result Update IT. 3-year price chart
1QFY2016 Result Update IT October 21, 2015 HCL Technologies Performance Highlights (` cr) Consl. 1QFY16 4QFY15 % chg (qoq) 1QFY15 % chg (yoy) Net revenue 10,097 9,777 3.3 8,735 15.6 EBIT 1,979 1,976 0.2
More informationHEG Ltd (HEG) 160. Performs well. Result Update. ICICI Securities Ltd Retail Equity Research. November 10, 2015
Result Update Rating matrix Rating : Hold Target : 175 Target Period : 12 months Potential Upside : 9% What s Changed? Target Changed from 185 to 175 EPS FY16E Unchanged from 9.1 to 9.5 EPS FY17E Unchanged
More informationSAIL (SAIL) 56. Dismal performance. Result Update. ICICI Securities Ltd Retail Equity Research. August 17, 2015
Result Update Rating matrix Rating : Sell Target : 50 Target Period : 12 months Potential Upside : -11% What s Changed? Target Changed from 60 to 50 EPS FY16E Changed from 4.8 to 1.1 EPS FY17E Changed
More informationWipro BUY. Performance Highlights CMP. `573 Target Price `719. 2QFY2016 Result Update IT. Investment Period 12 Months. 3-year price chart
Wipro Performance Highlights (` cr) 2QFY16 1QFY16 % chg (qoq) 2QFY15 % chg (yoy) Net revenue 12,514 12,371 1.2 11,684 7.1 EBITDA 2,729 2,606 4.7 2,482 9.9 EBITDA margin (%) 21.8 21.3 51bp 21.2 56bp PAT
More informationBata India Ltd. (BIL)
Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Q2FY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Bata India Ltd. (BIL) Cloudy quarter sunshine ahead;
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 196.40 Target Price 225.00 STYLAM INDUSTRIES LIMITED Result Update (PARENT BASIS): Q2 FY16 DECEMBER 16 th. 2015 ISIN: INE239C01012 12 th h, 2013 Index Details Stock Data Sector Plastic Products
More informationHow To Value Hpl In India
Materials - Containers & Packaging Oct 01, 2015 Bloomberg Code: HPPL IN India Research - Stock Broking Backed by Acquisition, Set to Augment Market Share New acquisition: In FY15, HPPL acquired 100% of
More informationTata Motors Ltd. Buy. New launches at domestic business as well as JLR to drive growth. February 12, 2016
February 12, 2016 Buy Tata Motors Industry: Auto and Auto Components Industry View: Positive l Result Update New launches at domestic business as well as JLR to drive growth JLR margins in line, standalone
More informationKingdee (268 HK) Buy (maintained) Target price: HK$3.58. Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$3.
Equity Research Information Technology Aug 2, 21 Kingdee (28 HK) Buy (maintained) Target price: HK$.8 Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$.8 Lower-than-expected
More informationBUY. Key Risks. Technology - Technology Services - Information Services. Nov 19, 2015. CRISIL Ltd. Recommendation (Rs.)
Technology - Technology Services - Information Services India Research - Stock Broking Economic recovery to boost revenues across business segments: The rating revenues witnessed 8% growth in 214 compared
More informationBUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value
UK Daily Letter 1 K3 Business Technology Group KBT : AIM : 144p BUY Target: 215p Bob Liao, CFA 44.20.7050.6654 bliao@canaccordgenuity.com COMPANY STATISTICS: 52-week Range: 0.82-1.50 Avg. Daily Vol. (000s):
More informationDATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015
BANKHAUS LAMPE // 1 DATRON AG Investor day supports our positive view 17/09/2015 Buy (Buy) 12.50 EUR (12.50 EUR ) Close 15/09/2015 9.75 EUR Bloomberg: DAR GY WKN: A0V9LA Sector Engineering Share price
More informationReliance Communication
3QFY214 Result Update Telecom February 11, 214 Reliance Communication Performance highlights (` cr) 3QFY14 2QFY14 % chg (qoq) 3QFY13 % chg (yoy) Net sales 5,43 5,394.2 5,31 1.9 EBITDA 1,845 1,887 (2.2)
More informationBharat Earth Movers (BEML)
2QFY2016 Result Update Capital Goods November 13, 2015 Bharat Earth Movers (BEML) Performance Highlights Quarterly highlights - Standalone Y/E March (` cr) 2QFY16 1QFY16 2QFY15 % chg (yoy) % chg (qoq)
More informationSadbhav Engineering. Weak execution, but strong order outlook. Source: Company Data; PL Research
Weak execution, but strong order outlook February 09, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating BUY Price Rs299 Target Price Rs340
More information2014 FIRST QUARTER RESULTS CONFERENCE CALL. May 15th, 2014
2014 FIRST QUARTER RESULTS CONFERENCE CALL May 15th, 2014 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The
More informationYES Bank HOLD. Not out of the woods yet; Asset quality remains a key monitorable. Institutional Equity Research. January 30, 2016. Target Price Rs788
January 3, 216 CMP* (Rs) 748 Upside/ (Downside) 5 Market Cap. (Rs bn) 314 Free Float 78 Shares O/S (mn) 419 YES Bank Not out of the woods yet; Asset quality remains a key monitorable YES Bank reported
More informationResearch Analysts. April 8, 2016. West Coast Paper Mills WESCOA Buy in the range of 75-78 96.00 68.00
Stocks on the move Scrip IDi I-Direct tcode Action Target Stoploss West Coast Paper Mills WESCOA Buy in the range of 75-78 96.00 68.00 Time Frame: 3 Months Research Analysts Dharmesh Shah dharmesh.shah@icicisecurities.com
More informationHow To Understand And Value Gsk Pharma
2QFY2016 Result Update Pharmaceutical November 2, 2015 GlaxoSmithKline Pharma Performance Highlights Y/E Mar (` cr) 2QFY2016 1QFY2016 % chg (qoq) 2QFY2015 % chg (yoy) Net Sales 692 622 11.3 739 (6.4) Other
More informationMargins to remain in mid 15% range for FY 16E, increase in FY 17E on operating leverage
January 29, 2016 Buy Maruti Suzuki (MSIL) Industry: Auto and Auto Components Industry View: Positive Result Update Prune estimates on margin dip, maintain BUY on good volume growth Q3 numbers hurt by slurry
More informationShriram Transport Finance Subsidiaries witness sharp increase in NPA
Shriram Transport Finance Subsidiaries witness sharp increase in NPA Shriram Transport Finance s (STFC) standalone performance was broadly in-line with our expectation but grossly disappointed on asset
More informationSep 2015: Strongest ever dispatch growth of 15% YoY
BSE Sensex S&P CNX 26,786 8,119 Stock Info Bloomberg COAL IN Equity Shares (m) 6,316.4 52-Week Range (INR) 7/301 1, 6, 12 Rel. Per (%) -11/-2/-5 M.Cap.(INR b)/(usd 2,084/31.9 b) AvgVal.INRm/Vol 000 1706/4532
More informationMuted results, stellar launch
INDUSTRY REAL ESTATE CMP (as on 03 Nov 2015) Rs 282 Target Price Rs 339 Nifty 8,061 Sensex 26,591 KEY STOCK DATA Bloomberg OBER IN No. of Shares (mn) 339 MCap (Rs bn) / ($ mn) 96/1,463 6m avg traded value
More informationAban Offshore (ABALLO) 180
Result Update Rating matrix Rating : Sell Target : 145 Target Period : 12 months Potential Upside : -19% What s changed? Target Changed from 223 to 145 EPS FY16E Changed from 73.1 to 9.7 EPS FY17E Changed
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 514.75 Target Price 590.00 DOC CODE: FOTL_090220164_3 IGARASHI MOTORS INDIA LTD Result Update (PARENT BASIS): Q3 FY16 FEBRUARY 9 th 2016 ISIN: INE188B01013 12 th h, 2013 Index Details Stock Data
More informationExhibit 1: Financial summary of First Tractor in 1H12-1H14 1H12 2H12 1H13 2H13 1H14 (% YoY)
Capital Goods Manufacturing ector August 29, 214 Company Report Rating: HOLD TP: HK$ 4.8 H-hare price (HK$) 5.17 Est. share price return (7.16%) Est. dividend yield 1.39% Est. total return (5.77%) First
More informationJindal Saw (SAWPIP) 64
Result Update November 20, 2015 Rating matrix Rating : Hold Target : 60 Target Period : 12 months Potential Upside : -6% What s Changed? Target Changed from 85 to 60 EPS FY16E Changed from 13.2 to 12.7
More informationBUY. JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16. CMP 298.00 Target Price 340.00. DECEMBER 29 th 2015.
BUY CMP 298.00 Target Price 340.00 JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16 DECEMBER 29 th 2015 ISIN: INE668F01031 12 th h, 2013 Index Details Stock Data Sector Household Products
More informationAxis Bank. Strong core performance. Source: Company Data; PL Research
Strong core performance January 17, 2011 Abhijit Majumder abhijitmajumder@plindia.com +91 22 66322236 Umang Shah umangshah@plindia.com +91 22 66322242 Rating BUY Price Rs1,230 Target Price Rs1,600 Implied
More informationState Bank of India. Source: Company Data; PL Research
Weak as expected; remain positive over medium term February 12, 2016 Nitin Kumar nitinkumar@plindia.com +91 22 66322236 Pritesh Bumb priteshbumb@plindia.com +91 22 66322232 Rating BUY Price Rs154 Target
More information